Publications from MSIF and other stakeholders in support of work on access to MS healthcare.
Access to treatment is a high priority for most people with MS. Convince decision-makers that MS treatments should be available in all health systems.
New publication highlights regional disparities in the management of MS
Advocacy examples from the global MS movement to inspire you today.
MSIF's work relating to off-label DMTs for MS
Advocating for the addition of MS treatments to the WHO Essential Medicines List
Addressing barriers to accessing treatment at a global, regional and national level
Collaborating with the Medicines Patent Pool as MSIF continues work on improving access to MS treatments
We look into these in more detail to understand how the treatment decisions are made by regulators.
What does research tell us about how DMTs affect the body’s immune response to COVID-19 vaccines?
New research, involving 874 people who had used disease-modifying therapies during the previous 5 years, has shown a link between more effective disease-modifying therapies and an increased level of employment, work attendance and productivity at work.
How the biological processes cause progression in different types of MS.